CBAY | Cymabay Therapeutics Inc
Category: Consumer goods
Quick infos Headquarters: Newark, California, United States Trade prices Volume: Market Cap: 234.56M Prev closed: Open: 3.04 High: 3.2 Low: 3.04 52 week low: 2.67 52 week high: 5.13 Dividends: No Dividends Next ER: August 10, 2023
Company Profile We are a clinical-stage biopharmaceutical company focused on developing and providing access to innovative therapies for patients with liver and other chronic diseases with high unmet medical need. We are evaluating seladelpar in primary biliary cholangitis (PBC). We also have a product program in earlier development that features a unique mechanism of action with potential in chronic diseases.
Earnings History Date EPS / Forecast Revenue / Forecast November 7, 2023 August 10, 2023 -0.01 / -0.231M / 11.38MBeat! May 15, 2023 -0.29 / -0.0934.2M / 28.47MBeat! March 16, 2023 -0.3 / -0.3- / 5MNovember 14, 2022 -0.28 / -0.3- / -view more
Historical Data Date Price Open High Low Vol Change ER Aug 7, 2023 12.14 12.34 12.47
11.89
991K -1.62% Aug 4, 2023 12.34 12.33 12.53
12.18
854K -0.24% Aug 3, 2023 12.37 12.46 12.53
12.17
698K -1.59% Aug 2, 2023 12.57 12.8 12.89
12.33
796K -2.56% Aug 1, 2023 12.9 13.24 13.25
12.68
1.2M -1.15% Jul 31, 2023 13.05 12.5 13.17
12.25
1.9M 6.27% Jul 28, 2023 12.28 11.86 12.5
11.79
1.3M 4.78% Jul 27, 2023 11.72 11.69 12.15
11.5
1.3M 1.47% Jul 26, 2023 11.55 11.79 11.84
11.41
780K -1.62% Jul 25, 2023 11.74 11.64 11.9
11.4
1.9M -0.76% view more
NASDAQ - Nasdaq Stock Market
More profiles and info about the company News
Is Swedish Orphan Biovitrum (BIOVF) Stock Outpacing Its Medical Peers This Year? finance.yahoo.com Sep 8, 2023 9:40 am
CymaBay Initiates IDEAL, a Phase 3 Placebo-Controlled, Randomized Study of Seladelpar in Patients with Primary Biliary Cholangitis and Incomplete Control of Alkaline Phosphatase finance.yahoo.com Sep 8, 2023 8:00 am
CymaBay's Seladelpar Achieves High Statistical Significance for the Primary and Key Secondary Endpoints in the Phase 3 RESPONSE Trial in Primary Biliary Cholangitis finance.yahoo.com Sep 8, 2023 7:00 am CymaBay says liver disease candidate outperformed in Phase 3 trial seekingalpha.com Sep 7, 2023 7:56 pm
CymaBay Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) finance.yahoo.com Aug 28, 2023 4:29 pm UBS starts Cymabay at buy, expecting positive Phase 3 data for seladelpar seekingalpha.com Aug 15, 2023 4:31 am
Twilio upgraded, Sealed Air downgraded: Wall Street's top analyst calls finance.yahoo.com Aug 11, 2023 9:36 am CymaBay Therapeutics GAAP EPS of -$0.01 beats by $0.22, revenue of $31.01M seekingalpha.com Aug 11, 2023 4:05 am
Recent Price Trend in CymaBay Therapeutics Inc. (CBAY) is Your Friend, Here's Why finance.yahoo.com Jul 17, 2023 8:50 am
11 Best Medical Stocks Under $10 finance.yahoo.com Jun 24, 2023 3:19 pm
CymaBay Therapeutics to Present New Data Highlighting Seladelpar's Unique Activity in Patients with Primary Biliary Cholangitis at The International Liver Congress 2023 finance.yahoo.com Jun 7, 2023 2:00 am
Q1 2023 CymaBay Therapeutics Inc Earnings Call finance.yahoo.com May 16, 2023 11:06 am
CymaBay Reports First Quarter 2023 Financial Results and Provides Corporate Update finance.yahoo.com May 15, 2023 4:04 pm
CymaBay Names Harish Shantharam Chief Financial Officer finance.yahoo.com May 9, 2023 8:00 am
Billionaire Joseph Edelman Snaps Up These 2 Biotech Stocks Heres Why You Should Follow finance.yahoo.com Apr 26, 2023 10:01 am
Wall Street Analysts Predict a 40.32% Upside in CymaBay Therapeutics Inc. (CBAY): Here's What You Should Know finance.yahoo.com Mar 28, 2023 9:55 am
CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Q4 2022 Earnings Call Transcript finance.yahoo.com Mar 20, 2023 9:04 pm
When Will CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Breakeven? finance.yahoo.com Mar 18, 2023 8:31 am CymaBay Therapeutics GAAP EPS of -$0.30 misses by $0.01 seekingalpha.com Mar 17, 2023 4:08 am
CymaBay Reports Fourth Quarter and Year Ended December 31, 2022 Financial Results and Provides Corporate Update finance.yahoo.com Mar 16, 2023 4:04 pm This company doesn't provide a dividend.
Talk about Cymabay Therapeutics Inc below in comments section below. Do you think you'll buy? Do you already have active trades now?
EarningsAhead is not affiliated with and this is not an endorsement of the companies featured above.
Share it with fellow traders:
or join discussions in FB below
(
FB comments )
If you are looking for News & events, Press Release, they are available on their Investors Relations site.
Consensus
If you want to help pay for server cost or for improving this tool. You can send it via Paypal .
Buy on Amazon Currency Trading For Dummies is a hands-on, user-friendly guide that explains how the foreign exchange (ForEx) market works and how you can become a part of it. Currency trading has many benefits, but it also has fast-changing financial-trading avenues. ForEx markets are always moving. So how do you keep up?
